Title

An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector

UMMS Affiliation

Division of Nuclear Medicine, Department of Radiology

Date

5-17-2008

Document Type

Article

Subjects

Algorithms; Animals; Antibodies, Monoclonal; Antibodies, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Indium Radioisotopes; Mice; Mice, Nude; Morpholines; Neoplasms; Radiopharmaceuticals; Tissue Distribution

Disciplines

Life Sciences | Medicine and Health Sciences

Abstract

In treating tumors by pretargeting, the antitumor antibody and the cytotoxic effector (e.g., toxins and radioactivity) are separately administered. Therefore, pretargeting is more complicated with many variables. We are conducting studies to understand the influence of each variable using a novel recognition pair of mutually complementary phosphorodiamidate morpholino oligomers (MORF/cMORF). Earlier we developed a semi-empirical model capable of accurately predicting the behavior of a radiolabeled cMORF effector with variations in dosages and timing. We have now extended the model to predict the effector behavior, in particular, its maximum percent tumor accumulation (MPTA) in mice pretargeted with three different MORF-conjugated antibodies (MN14, B72.3, and CC49). The MN14 and the CC49 target different antigens in the same tumor, whereas the CC49 and the B72.3 target the same antigen but with very different tumor accumulation. By comparing the pretargeting results of these three antibodies with our prediction, we confirmed that the MPTA of the radiolabeled cMORF effector in the LS174T tumor is independent of the antibodies. In conclusion, the MPTA cannot be improved through the use of different pretargeting antibodies, although different antibodies may improve the maximum absolute tumor accumulation, the heterogeneity, and/or the tumor-to-normal tissue ratios of the effector. This conclusion will apply equally well to effectors carrying a fluorescent probe, an anticancer agent, or a radioactive imaging agent.

Rights and Permissions

Citation: Mol Cancer Ther. 2008 May;7(5):1025-32. Link to article on publisher's site

DOI of Published Version

10.1158/1535-7163.MCT-07-2203

Related Resources

Link to Article in PubMed

Journal Title

Molecular cancer therapeutics

PubMed ID

18483292